Eradivir to Showcase Novel Antiviral Approaches at ESCMID Global and ICAR 2026
Eradivir a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, has announced its participation in two major international scientific conferences in 2026. The company will deliver oral presentations at ESCMID Global 2026 and the International Conference on Antiviral Research (ICAR) 2026, where it will highlight both clinical and preclinical findings from its influenza and respiratory syncytial virus (RSV) programs.
These presentations mark an important milestone for Eradivir as it continues to advance its proprietary therapeutic platform and expand its presence within the global infectious disease research community.
Focus on Innovative Antiviral Development
Eradivir is at the forefront of a new class of antiviral therapies built on its proprietary Bispecific Antigenic immuno-Therapy (BAiT™) platform. Unlike traditional antiviral drugs, which typically aim to directly inhibit viral replication, Eradivir’s approach leverages the body’s existing immune system to fight infections more efficiently.
At both ESCMID Global and ICAR 2026, the company will present data on its lead influenza candidate, EV25, and its RSV-focused candidate, EV148. These therapies represent a shift in antiviral strategy, focusing on immune system engagement rather than viral suppression alone.
The BAiT™ Platform: A New Mechanism of Action
The BAiT™ platform is designed to recruit naturally circulating antibodies already present in the human body. Instead of targeting the virus directly, Eradivir’s small molecules bind to infected cells and viral particles, effectively flagging them for immune recognition.
This mechanism triggers rapid and targeted immune clearance, allowing the body to eliminate infected cells more efficiently. One of the key advantages of this approach is that it operates independently of viral replication, which may provide therapeutic benefits even in later stages of infection.
Both EV25 and EV148 utilize this antibody-recruiting mechanism, positioning them as potentially versatile treatments for respiratory viral infections.
ESCMID Global 2026: Clinical Insights on EV25
At ESCMID Global 2026, Eradivir will present clinical data from its lead influenza candidate, EV25. The presentation, titled “Antiviral Efficacy of a Single Dose of EV25, A Novel Antibody Recruiting Molecule, in a Human Influenza A/H3N2 Challenge Trial,” will be delivered by Alan Cohen, MD, Acting Chief Medical Officer.
This presentation will focus on results from a human challenge study involving influenza A/H3N2, one of the most common and clinically significant strains of the virus. The study evaluates the efficacy of a single dose of EV25, providing insight into how quickly and effectively the therapy can trigger immune-mediated viral clearance.
The findings are expected to demonstrate the potential of EV25 as a fast-acting antiviral treatment that could reduce disease severity and duration. Given the ongoing global burden of influenza, such advancements could have meaningful implications for patient care and public health.
ICAR 2026: Expanding the Scope of Antiviral Innovation
At the International Conference on Antiviral Research (ICAR) 2026, Eradivir will deliver multiple presentations that further explore the capabilities of its BAiT™ platform.
Next-Generation Antivirals Using Immune System Engagement
The first ICAR presentation, titled “Next Generation Antivirals: Utilizing the Immune System via Bispecific Antigenic Immunotherapy (BAiT) Small Molecule Therapies to Treat Viral Infections and Their First Clinical Validation in Influenza,” will be presented by Jeffery Nielsen, PhD, Chief Technology Officer and Acting Chief Science Officer.
This session will provide a broader overview of the BAiT™ platform and its application in antiviral drug development. It will also highlight the first clinical validation of this approach in influenza, reinforcing the potential of immune-recruiting therapies as a new paradigm in antiviral treatment.
By showcasing both the scientific foundation and clinical progress of the platform, Eradivir aims to demonstrate how its technology could reshape the treatment landscape for viral infections.
Advancing RSV Treatment with EV148
In addition to its influenza program, Eradivir is making significant progress in addressing respiratory syncytial virus (RSV), a major cause of respiratory illness in infants and young children.
At ICAR 2026, the company will present preclinical data on EV148 in a session titled “A New Paradigm for RSV Treatment: EV148 Leverages Pre-Existing Immunity to Achieve Strain-Independent Antiviral Efficacy in Neonatal Lambs.” The presentation will be delivered by Conrrad Nichols, Director of Virology.
This study explores the efficacy of EV148 in neonatal lamb models, which are commonly used to simulate RSV infection in human infants. The results demonstrate that EV148 can harness pre-existing immunity to achieve antiviral effects that are independent of viral strain.
This strain-independent activity is particularly important for RSV, which exists in multiple variants. A treatment capable of working across different strains could significantly improve clinical outcomes and reduce the complexity of RSV management.
Potential Advantages Over Conventional Antivirals
Traditional antiviral therapies often face limitations such as resistance development and reduced efficacy in later stages of infection. Because they rely on inhibiting viral replication, their effectiveness may diminish once the virus has already spread extensively within the host.
Eradivir’s antibody-recruiting approach offers several potential advantages:
- Broad applicability: By leveraging the immune system, therapies may work across multiple viral strains.
- Rapid action: Immune-mediated clearance can occur quickly once infected cells are identified.
- Late-stage effectiveness: Since the mechanism does not depend on viral replication, treatment may still be beneficial after infection has progressed.
- Reduced resistance risk: Targeting host immune responses rather than viral machinery may lower the likelihood of resistance.
These attributes position EV25 and EV148 as promising candidates in the evolving field of antiviral therapeutics.
Strategic Importance of Global Scientific Conferences
Participation in ESCMID Global and ICAR 2026 provides Eradivir with an opportunity to share its latest research with leading scientists, clinicians, and industry stakeholders. These conferences serve as key platforms for exchanging ideas, validating scientific approaches, and fostering collaborations.
By presenting at both events, Eradivir underscores its commitment to transparency, scientific rigor, and innovation. The company’s presence also highlights the growing interest in immune-based antiviral strategies within the broader research community.
Looking Ahead: The Future of Antiviral Therapy
As viral infections continue to pose significant global health challenges, the need for innovative treatment approaches remains urgent. Eradivir’s BAiT™ platform represents a novel direction in antiviral research, focusing on empowering the body’s natural defenses rather than solely targeting the virus.
The data presented at ESCMID Global and ICAR 2026 will play a crucial role in advancing the development of EV25 and EV148. Positive outcomes could pave the way for further clinical trials and, ultimately, new treatment options for patients affected by influenza and RSV.
Eradivir’s upcoming presentations at ESCMID Global 2026 and ICAR 2026 highlight the company’s progress in developing next-generation antiviral therapies. Through its innovative BAiT™ platform, the company is exploring a fundamentally different approach to treating viral infections—one that leverages the body’s own immune system for rapid and effective response.
With promising data emerging from both clinical and preclinical studies, EV25 and EV148 could represent important advancements in the fight against respiratory viruses. As the scientific community gathers at these global conferences, Eradivir’s contributions are set to generate significant interest and potentially shape the future of antiviral treatment.
ABOUT ERADIVIR
Eradivir Inc. is a privately held, clinical-stage biotech company developing antibody-recruiting small molecules to treat disease. Using its proprietary BAiT™ (Bispecific Antigenic immuno-Therapy) platform, the company is advancing a pipeline of antibody-recruiting small molecules, including lead therapeutic EV25 for influenza and EV148 for RSV, with additional candidates in the pipeline targeting multiple diseases
